The correlation co-efficient was found to be 0.9986 for method A and 0.999 for method B, respectively. To study the precision of the method, the analysis of formulation was carried out for three times. The RSD (%) values were found to be 0.659 for method A and 0.558 for method B. Hence, the precision of the methods were confirmed. Further, the precision was confirmed by intermediate precision. The analysis of formulation was carried out for three times in the same day and on three successive days. The RSD (%) value for interday and intraday analysis of formulation was found to be less than 2% and is shown in Table 3. The accuracy of method was confirmed by recovery studies [Table 4]. A known amount of standard drug material was added with pre–analyzed formulation in different levels. The amount of drug recovered was calculated and the average percentage recovery was found to be in the range of 99.2989�C-99.63926% for method A and 98.9106�C99.4521% for method B. The low RSD (%) values ensured the accuracy of the method. CONCLUSIONS Two rapid, sensitive and accurate colorimetric methods for the determination of aceclofenac have been developed and validated. They are rapid, do not involve complicated extraction procedures and consume less time. The current spectrophotometric methods use cheap chemicals and inexpensive equipment while providing good sensitivity comparable even to the HPLC. This makes these methods highly suitable for quick routine analysis of aceclofenac in pharmaceutical dosage forms. ACKNOWLEDGMENTS The authors are thankful to the management of Institute of Pharmacy and Technology, Salipur for providing necessary facilities to carry out the present research work. Footnotes Source of Support: Nil Conflict of Interest: None declared.
The discovery and development of a new drug costs around $1 billion and it may take approximately 10 years for the drug to reach the marketplace.[1] Drug discovery and development is the process of generating compounds and evaluating all their properties to determine the feasibility of selecting one novel chemical entity (NCE) to become a safe and efficacious drug. Strategies in the drug discovery and drug development processes are undergoing radical change. For example, the contribution of pharmacokinetics (PK) to both processes is increasing.[2,3] Furthermore, toxicokinetics has now become established as an essential part of toxicity testing.[4,5] With this emphasis in the use of PK/toxicokinetics and the greater potencies of newer drugs, a sensitive and specific bioanalytical technique is essential. The emergence of the field of bioanalysis as a critical tool during the process of drug discovery and development is well understood and globally accepted.[6�C9] Over the past few decades, a plethora of assays has been continuously developed for NCEs to support various stages of discovery and development, including assays for important metabolites.